Robert R. Ruffolo Appointed at Nacuity Pharmaceuticals to its Board of Directors

Robert R. Ruffolo, Ph.D., joins Nacuity Pharmaceuticals’ Board of Directors.

FREMONT, CA: Nacuity Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing therapeutics for retinitis pigmentosa, cataracts, and other visual illnesses associated with oxidative stress, appoints Robert R. Ruffolo, Ph.D., to its Board of Directors. Dr. Ruffolo is an accomplished pharmaceutical executive with extensive expertise overseeing identifying, researching, and developing illness remedies.

"We are honored to have Dr. Ruffolo join our board. His expertise in scientific discovery, business strategy, and commercial development will be invaluable as we develop innovative solutions for patients who struggle with ocular diseases,' says Halden Conner, Chairman, CEO, and Co-Founder of Nacuity Pharmaceuticals Inc.

Dr. Ruffolo is currently employed with Versicolor Technologies as Chief Innovation Officer. From 2002 to 2008, he served as President of Research and Development and Senior Vice President of Wyeth Pharmaceuticals (now Pfizer). 

Before joining Wyeth, Dr. Ruffolo spent 17 years as Senior Vice President of Research and Development at SmithKline Beecham Pharmaceuticals (now GSK). He was instrumental in discovering and developing several commercially available products, including carvedilol, ropinerole, dobutamine, and eprosartan. Dr. Ruffolo has received numerous significant accolades, including the 2008 Discoverer's Award, for his pioneering work in discovering and developing carvedilol to treat congestive heart failure. Dr. Ruffolo is a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics, and Aridis Pharmaceuticals. Dr. Ruffolo earned a bachelor's degree in pharmacy and a doctorate in pharmacology from The Ohio State University.

“With its diverse library of novel antioxidant molecules, Nacuity is well-positioned to deliver treatments for ocular diseases caused by oxidative stress, including retinitis pigmentosa and cataracts,” says Dr. Ruffolo. “I’m delighted to join Nacuitys board to help support the team during this exciting time of clinical development and business growth.”